SpringerProtocols: Abstract: A Survey of Venous Thrombosis Models

A Survey of Venous Thrombosis Models

By: Walter P. Jeske^{2 3 4}, Omer Iqbal³, Jawed Fareed³, Brigitte Kaiser⁵

Abstract

Full Text

Download PDF (155K)

Animal models have played a crucial role in the development of new antithrombotic drugs during the past few decades. Through the use of these animal models, the differentiation between the anticoagulant and antithrombotic effects was first recognized. Drugs that were unable to produce a prolongation of blood clotting time were found to produce antithrombotic effects in animal models, and a recognition that endogenous effects in the intact animal resulting from the metabolic transformation of the drug and/or release of antithrombotic substances was appreciated. Without the use of intact animal models, such an observation would not have been possible.

Affiliation(s): (2) Department of Thoracic-Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL
(3) Department of Pathology, Loyola University Medical Center, Maywood, IL
(4) Cardiovascular Institute, Maywood, IL
(5) Center for Vascular Biology and Medicine Erfurt, Friedrich Schiller University Jena, Erfurt, Germany

Book Title: Anticoagulants, Antiplatelets, and Thrombolytics

Series: Methods in Molecular Medicine | Volume: 93 | Pub. Date: Nov-03-2003 | Page Range: 221-237 | DOI: 10.1385/1-59259-658-4:221

Subject: Molecular Medicine

References

Download References

1.	Jeske, W. P., Iqbal, O., Fareed, J., and Kaiser, B. (2003) A survey of animal models to develop novel antithrombotic agents, in New Therapeutic Agents in Thrombosis and Thrombolysis, 2nd ed. (Sasahara, A. A. and Loscalzo, J., eds.), Marcel Dekker, Inc., New York, pp. 9–32.

2.	Wessler, S., Reimer, S. M., and Sheps, M. C. (1959) Biologic assay of a thrombosisinducing activity in human serum. J. Appl. Physiol. 14, 943–946.

3.	Meuleman, D. G., Hobbelen, P. M., Van Dinther, T. G., Vogel, G. M., Van Boeckel, C. A., and Moelker, H. C. (1991) Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than the natural pentasaccharide. Semin. Thromb. Hemost. 17 (Suppl. 1), 112–117.

4.	Carrie, D., Caranobe, C., Saivin, S., Houin, G., Petitou, M., Lormeau, J. C, et al. (1994) Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY 216. Blood 84(8), 2571–2577.

5.	Bara, L., Bloch, M. F., and Samama, M. M. (1992) A comparative study of recombinant hirudin and standard heparin in the Wessler model. Thromb. Res. 68(2), 167–174.

6.	Saivin, S., Petitou, M., Lormeau, J. C, Dupouy, D., Sie, P., Caranobe, C, et al. (1992) Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects. Thromb. Haemostasis 67(3), 346–351.

7.	Thomas, D. P., Gray, E., and Merton, R. E. (1990) Potentiation of the antithrombotic action of dermatan sulfate by small amounts of heparin. Thromb. Haemostasis 64(2), 290–293.

8.	Walenga, J. M., Fareed, J., Petitou, M., Samama, M., Lormeau, J. C., and Choay, J. (1986) Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb. Res. 43(2), 243–248.

9.	Peyrou, V., Lormeau, J. C., Caranobe, C., Gabaig, A. M., Crepon, B., Saivin, S., et al. (1994) Pharmacologic properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thromb. Haemostasis 72(2), 268–274.

10.	Saivin, S., Caranobe, C., Petitou, M., Lormeau, J. C., Level, M., Crepon, B., et al. (1992) Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulfate in rabbits. Br. J. Haematol. 80(4), 509–513.

11.	Walenga, J. M., Petitou, M., Lormeau, J. C., Samama, M., Fareed, J., and Choay, J. (1987) Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. 46(2), 187–198.

12.	Vlasuk, G. P., Ramjit, D., Fujita, T., Dunwiddie, C. T., Nutt, E. M., Smith, D. E., et al. (1991) Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemostasis 65(3), 257–262.

13.	Bacher, P., Walenga, J. M., Iqbal, O., Bajusz, S., Breddin, K., and Fareed, J. (1993) The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. Thromb. Res. 71(4), 251–263.

14.	Millet, J., Theveniaux, J., and Brown, N. L. (1994) The venous antithrombotic profile of naroparcil in the rabbit. Thromb. Haemostasis 72(6), 874–879.

15.	Callas, D. D., Bacher, P., and Fareed, J. (1995) Studies on the thrombogenic effects of recombinant tissue factor. In vivo versus ex vivo findings. Semin. Thromb. Hemost. 21(2), 166–176.

16.	Fareed, J., Walenga, J. M., Kumar, A., and Rock, A. (1985) A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin. Thromb. Hemost. 11(2), 155–175.

17.	Bacher, P., Welzel, D., Iqbal, O., Hoppensteadt, D., Callas, D., Walenga, J. M., et al. (1992) The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb. Res. 66, 151–158.

18.	Raake, W. and Elling, H. (1989) Rat jugular vein hemostasis—a new model for testing antithrombotic agents. Thromb. Res. 53, 73–77.

19.	Raake, W., Klauser, R. J., Meinetsberger, E., Zeiller, P., and Elling, H. (1991) Pharmacologic profile of the antithrombotic and bleeding actions of sulfated lactobionic acid amides. Semin. Thromb. Hemost. 17 (Suppl. 1), 129–135.

20.	Hayes, J. M., Jeske, W., Callas, D., Iqbal, O., and Fareed, J. (1996) Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model. Thromb. Res. 82(2), 187–191.

21.	Kaiser, B. (1995) Effect of tissue factor pathway inhibitor (TFPI) on venous thrombus formation and rethrombosis after lysis in the jugular veins of rabbits. Thromb. Haemostasis 73(6), 944.

22.	Kaiser, B., Simon, A., and Markwardt, F. (1990) Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb. Haemostasis 63(1), 44–47.

23.	Lyle, E. M., Fujita, T., Conner, M. W., Connolly, T. M., Vlasuk, G. P., and Lynch, J. L. (1995) Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury. J. Pharmacol. Toxicol. Methods 33(1), 53–61.

24.	Katsuragawa, M., Fujiwara, H., Kawamura, A., Htay, T., Yoshikuni, Y., Mori, K., et al. (1993) An animal model of coronary thrombosis and thrombolysis—comparisons of vascular damage and thrombus formation in the coronary and femoral arteries after balloon angioplasty. Jpn. Circ. J. 57(10), 1000–1006.

25.	Kaiser, B. and Markwardt, F. (1986) Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. Thromb. Haemostasis 55(2), 194–196.

26.	Heras, M., Chesebro, J. H., Penny, W. J., Bailey, K. R., Lam, J. Y. T., Holmes, D. R., et al. (1988) Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 78, 654–660.

27.	Harker, L. A. (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am. J. Cardiol. 60, 20B–28B.

28.	Kurz, K. D., Main, B. W., and Sandusky, G. I. (1990) Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 60, 269–280.

29.	Schumacher, W. A., Heran, C. L., Steinbacher, T. E., Youssef, S., and Ogletree, M. L. (1993) Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. J. Cardiovasc. Pharmacol. 22, 526–533.

30.	Elg, M., Gustafsson, D., and Carlsson, S. (1999) Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. 94(3), 187–197.

31.	Deschenes, I., Finkle, C. D., and Winocour, P. D. (1998) Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Thromb. Haemostasis 80(1), 186–191.

32.	Roesken, F., Ruecker, M., Vollmar, B., Boeckel, N., Morgenstern, E., and Menger, M. D. (1997) A new model for quantitative in vivo microscopic analysis of thrombus formation and vascular recanalisation: the ear of the hairless (hr/hr) mouse. Thromb. Haemostasis 78(5), 1408–1414.

33.	Sanaibadi, A. R., Umemura, K., Matsimoto, N., Sakuma, S., and Nakashima, M. (1995) Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb. Haemostasis 73, 868–872.

34.	Hokamura, K., Umemura, K., Makamura, N., Watanabe, M., Takashima, T., and Nakashima, M. (1998) Effect of lipo-pro-prostaglandin EI, AS-013, on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot. Essen. Fatty Acids 59(3), 203–207.

35.	Weichert, W. and Breddin, H. K. (1988) Effect of low-molecular-weight heparin on laser-induced thrombus formation in rat mesenteric vessels. Haemostasis 18S3, 55–63.

36.	Yamashita, T., Tsuda, Y., Konishi, Y., Okada, Y., Matsuoka, A., Giddings, J. C, et al. (1998) The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb. Res. 90(5), 199–206.

37.	Yamamoto, J., Ishii, I., Okita, N., Sasaki, Y., Yamashita, T., Matsuoka, A., et al. (1997) The differential involvement of von Willebrand factor, fibrinogen and fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. Jpn. J. Phys. 47(5), 431–441.

38.	Yamashita, T., Tsuji, T., Matsuoka, A., Giddings, J. C., and Yamamoto, J. (1997) The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb. Res. 85(1), 45–51.

39.	Herbert, J. M., Bernat, A., and Maffrand, J. P. (1992) Importance of platelets in experimental venous thrombosis in rats. Blood 80, 2281–2286.

40.	Berry, C. N., Girard, D., Lochot, S., and Lecoffre, C. (1994) Antithrombotic actions of argatroban in rat models of venous, “mixed” and arterial thrombosis, and its effects on the tail transection bleeding time. Br. J. Pharmacol. 113, 1209–1214.

41.	Seth, P., Kumari, R., Dikshit, M., and Srimal, R. C. (1994) Effect of platelet activating factor antagonists in different models of thrombosis. Thromb. Res. 76, 503–512.

42.	Fu, K., Izquierdo, R., Vandevender, D., Warpeha, R. L., Wolf, H., and Fareed, J. (1997) Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model. Thromb. Res. 86(5), 355–361.

43.	Korompilias, A. V., Chen, L. E., Seaber, A. V., and Urbaniak, J. R. (1997) Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate or crushed arterial anastomoses. J. Hand Surg. 22(3), 540–546.

44.	Stockmans, F., Stassen, J. M., Vermylen, J., Hoylaerts, M. F., and Nystrom, A. (1997) A technique to investigate mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin and G-4120. Ann. Plastic Surg. 38(1), 63–68.

45.	Van Wyk, V., Neethling, W. M. L., Badenhorst, P. N., and Kotze, H. F. (1998) r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons. J. Cardiovasc. Surg. 39, 633–639.

46.	Dewanjee, M. K., Wu, S. M., and Hsu, L. C. (2000) Effect of heparin reversal and fresh platelet transfusion on platelet emboli post-cardiopulmonary bypass surgery in a pig model. ASAIO J. 46, 313–318.

47.	Dewanjee, M. K., Wu, S., Kapadvanjwala, M., et al. (1996) Reduction of platelet thrombi and emboli by L-arginine infusion during cardiopulmonary bypass in a pig model. J. Thromb. Thrombolysis 3, 339–356.

48.	Walenga, J. M., Bakhos, M., Messmore, H. L., Fareed, J., and Pifarre, R. (1991) Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann. Thorac. Surg. 51, 271–277.

49.	Henny, Ch. P., TenCate, H., TenCate, J. W., Moulijn, A. C., Sie, T. H., Warren, P., et al. (1985) A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. J. Clin. Lab. Med. 106, 187–196.

50.	Murray, W. G. (1985) A preliminary study of low molecular weight heparin in aortocoronay bypass surgery, in Low molecular weight heparin in surgical practice (Master of surgery thesis) (Murray, W G.), University of London, London, UK, 266.

Comments (Loading...)

Post comment/View all comments